AI-generated analysis. Always verify with the original filing.
Lipocine Inc. reported a net loss of $9.6 million for fiscal year 2025, driven by an operating loss of $10.4 million. Total revenues were $2.0 million, consisting of $1.5 million in license revenue and $477,000 in royalty revenue. Operating expenses totaled $12.3 million, with research and development costs of $8.6 million and general and administrative expenses of $3.8 million. The company generated $744,000 in other income, primarily from interest and investment income. Cash used in operating activities was $9.8 million, partially offset by $5.9 million in cash provided by investing activities and $2.9 million from financing activities. The company ended the year with $4.8 million in cash and cash equivalents and total assets of $17.0 million. The accumulated deficit increased to $209.4 million, reflecting continued investment in research and development activities.
Lipocine Inc. reported a net loss of $9.6 million for fiscal year 2025, representing a continuation of the company's development-stage operations. The operating loss was $10.4 million, driven by total operating expenses of $12.3 million against revenues of $2.0 million. The company generated $744,000 in other income, primarily from interest and investment income, which partially offset the operating loss. Basic and diluted loss per share was $2.00, based on weighted average common shares outstanding of 5.4 million and 5.7 million respectively. Comprehensive loss matched the net loss at $9.6 million, with a minor adjustment for net unrealized loss on available-for-sale securities of $5,000.
The company generated total revenues of $2.0 million for fiscal year 2025, consisting of $1.5 million in license revenue and $477,000 in royalty revenue. No segment breakdown or geographic mix was provided in the available data. The revenue sources appear to be derived from licensing agreements and royalty arrangements related to the company's pharmaceutical development programs. No year-over-year comparison data was provided in the source material to assess revenue growth trends.
The company reported negative operating margins due to its development-stage status and significant investment in research and development. Operating expenses totaled $12.3 million, with research and development accounting for $8.6 million (70% of total operating expenses) and general and administrative expenses comprising $3.8 million (31% of total operating expenses). No gross profit or gross margin figures were provided in the source data, as the company appears to be primarily focused on development activities rather than product sales.
Cash used in operating activities was $9.8 million, primarily driven by the net loss of $9.6 million. The company generated $5.9 million in cash from investing activities, mainly from maturities of marketable investment securities of $20.6 million offset by purchases of $14.7 million. Financing activities provided $2.9 million from net proceeds from sale of common stock through ATM offerings. The company ended the period with $4.8 million in cash and cash equivalents and total assets of $17.0 million. Total liabilities were $2.5 million, resulting in stockholders' equity of $14.5 million and an accumulated deficit of $209.4 million.
No specific management guidance, strategic priorities, or forward-looking statements were provided in the available financial data. The company's continued investment in research and development ($8.6 million) suggests ongoing focus on pharmaceutical development programs. The financing activities through ATM offerings indicate continued reliance on equity markets for funding. The accumulated deficit of $209.4 million reflects the long-term nature of pharmaceutical development and the company's stage in the product development lifecycle.
EPS
-$2.00
Revenue
$2.0M
Net Income
-$9.6M